Microchip is a mid-cycle recovery play on the broad-line 8-bit/16-bit/32-bit MCU + analog franchise. After an unprecedented FY2025 downcycle (revenue -42% YoY, trough operating margin -10%), Steve Sanghi's return as CEO (Nov 2024) and his nine-point recovery plan have restored sequential growth (Q3 FY2026 revenue $1.186B, +15.6% YoY) and reclaimed ~1,000 bps of gross margin from the 52% trough to 60.5%. The thesis is that MCHP can return to ~65% non-GAAP gross margin and mid-30% operating margin by CY2027 as distributor inventory (now 27 days vs 33 in March 2025) normalizes, Fab 2 closure saves ~$90M/year, and the PCIe Gen 6 Switchtec data-center franchise adds $100M+ in CY2027 revenue. Upside is leveraged to margin recovery, not unit growth.
| Scenario | Prob. | Target | Driver |
|---|---|---|---|
| Bull | 30% | $120.00 | Non-GAAP gross margin reaches 65% long-term target by Q4 CY2027 as Fab 2 savings + utilization normalize |
| Base | 50% | $99.00 | Non-GAAP gross margin recovers to 63-64% by end of CY2027 (vs 65% target) — underutilization persists as a modest residual headwind |
| Bear | 20% | $58.00 | Distributor inventory correction re-accelerates (days back above 35) as industrial/auto demand softens |
MCHP --rerate --accept-latest-close (manual)
Cascade-thesis-change from (NXPI peer read-through)
Phase C GPT-5.4 cross-review
Deep research pass
Positioning skews toward near-term upside